Key result
Andexanet alfa at 100 µg/ml effectively neutralized the anti-coagulant effects of bovine, ovine, and porcine heparins in whole blood ACT and aPTT assays, comparable to protamine sulfate.
Why the study?
This study aimed to investigate the comparative neutralization profiles of andexanet alfa and protamine sulfate for unfractionated heparins of bovine, ovine, and porcine origin.
Does andexanet alfa neutralize the anticoagulant effects of unfractionated heparin in vitro compared to protamine sulfate?
Population
Whole blood supplemented with unfractionated heparins of bovine, ovine, and porcine origin
Comparison
Andexanet alfa at 100 µg/ml vs protamine sulfate at 25 µg/ml
Design
In-vitro laboratory study
Authors
Loading...
AA nearly matches protamine for UFH neutralization across origins in vitro; leaves open clinical validation before any practice consideration.
Does andexanet alfa neutralize the anticoagulant effects of unfractionated heparin in vitro compared to protamine sulfate?
Andexanet alfa demonstrates comparable efficacy to protamine sulfate in neutralizing the anticoagulant effects of unfractionated heparin in in-vitro ACT and aPTT assays, suggesting potential utility as a heparin reversal agent.
Siddiqui et al. (2024) studied Anticoagulation reversal. Andexanet alfa vs. Protamine sulfate (25 µg/ml) was evaluated on Neutralization of anti-coagulant effects of heparins (ACT, aPTT, anti-Xa, anti-IIa, thrombin generation). Andexanet alfa at 100 µg/ml effectively neutralized the anti-coagulant effects of bovine, ovine, and porcine heparins in whole blood ACT and aPTT assays, comparable to protamine sulfate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: